http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#Head
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#provenance
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#pubinfo
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion
http://purl.obolibrary.org/obo/DOID_1926
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1926
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09039
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
http://www.w3.org/2000/01/rdf-schema#label
cerdelga is indicated for the long term treatment of adult patients with gaucher disease type 1 gd1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test see dosage and administration 2 1 cerdelga is a glucosylceramide synthase inhibitor indicated for the long term treatment of adult patients with gaucher disease type 1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test 1 limitations of use cyp2d6 ultra rapid metabolizers may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect 1 a specific dosage cannot be recommended for cyp2d6 indeterminate metabolizers 1 limitations of use patients who are cyp2d6 ultra rapid metabolizers urms may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect see clinical studies 14 a specific dosage cannot be recommended for those patients whose cyp2d6 genotype cannot be determined indeterminate metabolizers see clinical studies 14
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09039
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#provenance
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#pubinfo
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig
http://purl.org/nanopub/x/hasSignature
ETYCD+lirERQF6b0Ei6c6patvEaJ9gFUT+twB6KJmuH22oOL5L4gPyH1dr8AlkH0cpgLmmS+3ETBypfg4UhEKVBPVJ+dvSApBSa4po6WF7VI4BCSa+s2AfHwJQKxo2/wY32tV9erK/V/wwzt1vSIerAJz1gE78DgvqJU+A8hxqs=
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://purl.org/dc/terms/created
2021-06-12T14:23:10.024+02:00
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs